SGHT earnings analysis
What we found in SGHT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sight Sciences, Inc. reported Q1 2026 financials showing a revenue of $19.7 million, exceeding consensus estimates of $18.55 million. However, the diluted EPS of -0.24 missed expectations of -0.20, reflecting ongoing challenges in profitability. The company indicated strong growth in its Interventional Dry Eye segment, contributing to an overall revenue increase of 12.5% year-over-year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surpass Estimates
- Revenue reached $19.7 million, exceeding the estimate of $18.55 million by 6.2%.
- Strong Interventional Dry Eye Growth
- Interventional Dry Eye segment revenue grew to $1.4 million, an increase of 244% compared to the prior year.
- Improved Gross Margin Stability
- Total gross margin was stable at 86.2%, maintaining profitability despite challenges.
- Reduced R&D Expenses
- R&D expenses decreased by 42.5% year-over-year to $2.5 million.
- Decrease in Operational Losses
- Loss from operations improved to $12.4 million, a reduction of 10.4% from the prior year.
- Increase in Cash Reserves
- Cash and cash equivalents increased to $85 million, reflecting stronger liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continuing Operating Loss
- Net loss for the quarter was $12.98 million, indicating persistent profitability challenges.
- High SG&A Expenses
- SG&A expenses rose to $26.8 million, driven by $5.4 million in legal expenses from ongoing litigation.
- Dependency on Third-Party Manufacturers
- The reliance on third-party suppliers for components exposes the company to supply chain risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.24
- Gross margin
- 86.2%
- Segment
- Interventional Glaucoma: $18.3M
- Segment
- Interventional Dry Eye: $1.4M
What they said about what is next.
No explicit quantitative guidance provided in the filing.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 4, 2026
- Sight Sciences reported Q4 2025 revenue of $20.385M and EPS of -$0.08, modestly beating consensus (revenue beat +0.23%, EPS beat). Margins and profitability show a clear trajectory of improvement through 2025 (gross…
- 10-Q · August 7, 2025
- Sight Sciences reported Q2 2025 revenue of $19,564,000 and GAAP diluted loss per share of $(0.23). Gross margin remained high at 84.8% while operating loss narrowed modestly to $(11,667,000) for the quarter. Cash…
- 10-Q · May 8, 2025
- Sight Sciences reported Q1 revenue of $17,508,000 (Q1 2024: $19,265,000), with gross margin holding at 86.2% but operating margin deteriorating to -79.2%. Net loss was $14,154,000 (EPS -$0.28), cash and cash equivalents…
- 10-K · March 7, 2025
- Sight Sciences’ 10-K (fiscal year ended December 31, 2024) emphasizes a dual-product strategy: Surgical Glaucoma (OMNI, SION) and Dry Eye (TearCare), with Surgical Glaucoma driving the business (95% of 2024 revenue).…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SGHT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever